Page last updated: 2024-08-21

indazoles and Dysmyelopoietic Syndromes

indazoles has been researched along with Dysmyelopoietic Syndromes in 6 studies

Research

Studies (6)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (16.67)	29.6817
2010's	5 (83.33)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
O'Cearbhaill, RE	1
Bohannan, Z; Cable, L; Calvo, MC; Garcia-Manero, G; Hogeland, G; Jabbour, E; Kantarjian, H; Khoury, HJ; Komrokji, R; Lancet, J; List, A; Maloney, L; Ptaszynski, M; Rush, S; Winski, SL	1
Bohannan, ZS; Gañán-Gómez, I; Garcia-Manero, G	1
Akutagawa, J; Braun, BS; Chang, T; Cottonham, CL; Dail, M; Epstein, I; Friedman, LS; Huang, TQ; Quirindongo-Crespo, M; Sampath, D; Slusher, BS	1
Assal, A; Bachegowda, L; Bartenstein, M; Bhagat, T; Bhattacharyya, S; Boultwood, J; Brown, S; Burgess, LE; Chantry, D; Garrus, J; Giricz, O; Gordon-Mitchell, S; Gross, S; Guha, C; Hogeland, G; Mantzaris, I; Morrone, K; Munson, M; Nwankwo, G; Pellagatti, A; Platanias, L; Pradhan, K; Ramachandra, N; Rizzi, J; Rodriguez, M; Schinke, C; Shahnaz, S; Shastri, A; Steidl, U; Sukrithan, V; Verma, A; Winski, SL; Wollenberg, L; Wright, D; Yu, Y; Zou, Y	1
Bellamy, WT; Beran, M; Bycott, P; Estrov, Z; Giles, FJ; List, AF; O'Brien, SM; Pithavala, Y; Ravandi, F; Reich, SD; Steinfeldt, H; Verstovsek, S; Yee, KW	1

Trials

2 trial(s) available for indazoles and Dysmyelopoietic Syndromes

Article	Year
A phase I study of oral ARRY-614, a p38 MAPK/Tie2 dual inhibitor, in patients with low or intermediate-1 risk myelodysplastic syndromes. Clinical cancer research : an official journal of the American Association for Cancer Research, 2015, Mar-01, Volume: 21, Issue:5 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone Marrow; Female; Humans; Indazoles; Male; Middle Aged; Myelodysplastic Syndromes; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Receptor, TIE-2; Treatment Outcome; Urea	2015
The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Leukemia research, 2006, Volume: 30, Issue:7 Topics: Acute Disease; Administration, Oral; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Imidazoles; Immunohistochemistry; Indazoles; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Placenta Growth Factor; Predictive Value of Tests; Pregnancy Proteins; Prognosis; Proto-Oncogene Proteins c-kit; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2	2006

Article

Year

A phase I study of oral ARRY-614, a p38 MAPK/Tie2 dual inhibitor, in patients with low or intermediate-1 risk myelodysplastic syndromes.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2015, Mar-01, Volume: 21, Issue:5

Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone Marrow; Female; Humans; Indazoles; Male; Middle Aged; Myelodysplastic Syndromes; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Receptor, TIE-2; Treatment Outcome; Urea

2015

The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

Leukemia research, 2006, Volume: 30, Issue:7

Topics: Acute Disease; Administration, Oral; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Imidazoles; Immunohistochemistry; Indazoles; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Placenta Growth Factor; Predictive Value of Tests; Pregnancy Proteins; Prognosis; Proto-Oncogene Proteins c-kit; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2

2006

Other Studies

4 other study(ies) available for indazoles and Dysmyelopoietic Syndromes

Article	Year
Using PARP Inhibitors in Advanced Ovarian Cancer. Oncology (Williston Park, N.Y.), 2018, 07-15, Volume: 32, Issue:7 Topics: Anemia; Creatinine; Drug Administration Schedule; Drug Interactions; Exanthema; Fatigue; Female; Genes, BRCA1; Genes, BRCA2; Heart Rate; Humans; Hypertension; Indazoles; Leukopenia; Mutation; Myelodysplastic Syndromes; Nasopharyngitis; Nausea; Ovarian Neoplasms; Piperidines; Pneumonia; Poly(ADP-ribose) Polymerase Inhibitors; Thrombocytopenia; Transaminases; Vomiting	2018
p38 MAPK in MDS. Aging, 2015, Volume: 7, Issue:6 Topics: Gene Expression Regulation; Humans; Indazoles; Myelodysplastic Syndromes; p38 Mitogen-Activated Protein Kinases; Urea	2015
Targeting the PI3K/Akt pathway in murine MDS/MPN driven by hyperactive Ras. Leukemia, 2016, Volume: 30, Issue:6 Topics: Animals; Heterocyclic Compounds, 3-Ring; Indazoles; Leukemia, Myelomonocytic, Chronic; Leukemia, Myelomonocytic, Juvenile; MAP Kinase Signaling System; Mice; Myelodysplastic Syndromes; Myeloproliferative Disorders; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; ras Proteins; Signal Transduction; Sulfonamides	2016
Pexmetinib: A Novel Dual Inhibitor of Tie2 and p38 MAPK with Efficacy in Preclinical Models of Myelodysplastic Syndromes and Acute Myeloid Leukemia. Cancer research, 2016, 08-15, Volume: 76, Issue:16 Topics: Angiopoietin-1; Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Screening Assays, Antitumor; Gene Knockdown Techniques; Humans; Indazoles; Leukemia, Myeloid, Acute; Male; Mice; Myelodysplastic Syndromes; p38 Mitogen-Activated Protein Kinases; Proportional Hazards Models; Receptor, TIE-2; Urea	2016